NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES FIRST GENERIC VERSION OF THE EPILEPSY MEDICINE LACOSAMIDE IN AUSTRALIA
We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be affordable and available for all patients around the world – irrespective of their income level or nationality. That´s why we are happy to share that we have successfully prepared the launch of the generic version of Lacosamide for a market entry on day one after patent expiration in Australia.
Lacosamide is used for the treatment of seizures improving the life of patients suffering from epilepsy. The tablets will be marketed in Australia in the strengths 50mg, 100mg, 150mg, and 200mg by our partner, one of the biggest generic pharmaceutical companies in the world. Our product has already been launched in time in several patent-free European markets. A launch in further countries will follow as soon as the patents of the originator product expire.
With this early market entry, TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or please visit us on: www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
